 CAMBRIDGE, Mass., July 23, 2020 GLOBE NEWSWIRE -- Evelo Biosciences Nasdaq:EVLO, a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 30, 2020 to report its second quarter 2020 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 domestic or 409-937-8909 international and refer to conference ID 7048016. A live webcast of the event will also be available under News and Events in the Investors section of Evelos website at The archived webcast will be available on Evelos website approximately two hours after the completion of the event and will be available for 30 days following the call.About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAXTM, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The companys first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelos therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.For more information, please visit and engage with Evelo on LinkedIn.Contact Evelo Biosciences Jessica Cotrone, 978-760-5622 